RecruitingRecruiting
iDose TR Administration in an Office-Based Surgery Setting
NCT07816692 · Glaukos Corporation
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Real-World Evidence Observational Study to Evaluate the Safety of iDose® TR (Travoprost Intracameral Implant) 75 µg in an Office-Based Surgery Setting
About this study
This study is a multicenter, single arm, open-label trial in adult subjects with open-angle glaucoma or ocular hypertension. The objective of the study is to assess the safety profile of iDose TR administration in an office-based surgery setting.
Eligibility criteria
Inclusion Criteria:
* Diagnosis of Open angle glaucoma (OAG) or ocular hypertension (OHT)
Exclusion Criteria:
* Prior administration of iDose TR or administration of an investigational intracameral implant in the study eye
* Active ocular infection or inflammation
* History of hypersensitivity to travoprost or implant components
* Recent ocular surgery
* Uncontrolled systemic disease
* Any condition preventing safe implantation
Study design
Enrollment target: 30 participants
Age groups: adult, older_adult
Timeline
Starts: 2026-05-13
Estimated completion: 2027-03
Last updated: 2026-09-30
Interventions
Combination Product: iDose TR (travoprost intracameral implant) 75 µg
Primary outcomes
- • Successful administration of iDose TR in an office-based surgical setting. (3 months)
Sponsor
Glaukos Corporation · industry
Contacts & investigators
ContactStudy Director · contact · ClinicalResearch@glaukos.com · 949-739-8749
All locations (1)
Glaukos Investigative SiteRecruiting
Austin, Texas, United States